ClinicalTrials.gg
CompletedNCT00909844DECAPUBUpdated Jan 15, 2019Results posted

Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up Study

A Phase 3 interventional study of Triptorelin (I.N.N.) in Precocious Puberty, sponsored by Ipsen. Completed at 10 sites in France. Per ClinicalTrials.gov, last updated 2019-01-15.

Sponsored by Ipsen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Sex
All
01

Study summary

The purpose of the protocol is to assess the efficacy of triptorelin 11.25 mg with respect to the proportion of children who maintain a regression or stabilisation of sexual maturity until the end of the study.

02

Conditions studied

  • Precocious Puberty

Browse trials for

03

In context

Puberty, Precocious

75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.

This study's enrollment of 35 is below the median of 64 across 47 interventional studies indexed under Puberty, Precocious.

Browse Puberty, Precocious studies →

Lead sponsor

Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.

Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The child must have completed study 2-54-52014-143
  • The child must have an effective response to 2 injections of triptorelin 11.25 mg according to investigator's evaluation with no significant treatment side effects

Exclusion criteria

Exclusion Criteria:

  • The patient has a known to any of the test materials or related compounds
  • The patient is unable or unwilling to comply fully with the protocol
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Triptorelin

    Drug: Triptorelin (I.N.N.)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Children With a Stabilisation or Regression of Tanner Pubertal Stage at the End of the Study (Final Visit), Compared to Pretreatment (Month -6) and Baseline (Month 0)

    The primary objective was to assess efficacy of triptorelin pamoate 11.25 mg with respect to percentage of children maintaining a regression or stabilisation of sexual maturity (based on Tanner breast \[girls\] or genital \[boys\] pubertal stage) until end of study. Study treatment lasted until end of the therapeutic period; visits for Months 36 and 48 were optional since a child may have already finished the study at a prior visit. The Final Visit only occurred if the child did not end the study by a complete visit such as at Months 24, 36 or 48. Results are presented only for percentage of girls with regression or stabilisation of Tanner breast pubertal stage (n=34). Since only one boy was included in the study, results for this outcome measure were listed only and no statistical analysis was performed. Please also note additional post-hoc analysis for regression or stabilisation of Tanner breast pubertal stage which applied the variable Last Visit on Treatment instead of Final Visit.

    Time frame: Months 12, 24, 36, 48 and Final Visit (if applicable; up to 63 months)

Secondary outcomes

  1. Percentage of Patients With a Suppressed Luteinizing Hormone (LH) Response to Gonadotropin-Releasing Hormone (GnRH) Test

    A suppressed LH response to the GnRH test was defined as a stimulated peak of LH ≤3 international units per litre (IU/L). Percentage of patients who had a suppressed LH response to the GnRH test is reported. It should be noted that almost no hormonal data was collected after Baseline; all data analysed is presented.

    Time frame: Months -6, 0 and 36

  2. Levels of Oestradiol in Girls or Testosterone in Boys Both Measured by Radioimmunoassay (RIA)

    Mean levels of oestradiol in girls or testosterone in boys are reported. It should be noted that almost no hormonal data was collected after Baseline; all data analysed is presented.

    Time frame: Months -6, 0, 12, 36 and Final Visit (up to 63 months)

  3. Percentage of Patients With a Suppressed Follicle Stimulating Hormone (FSH) Response to GnRH Test

    A suppressed FSH response to the GnRH test was defined as a stimulated peak of FSH ≤3 IU/L. Percentage of patients who had a suppressed FSH response to the GnRH test is reported. It should be noted that almost no hormonal data was collected after Baseline; all data analysed is presented.

    Time frame: Months -6, 0 and 36

  4. Body Mass Index (BMI) for Chronological Age Variation

    Mean changes of BMI from Pretreatment and from Baseline are reported. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.

    Time frame: Months -6, 0, 12, 24, 36, 48 and Final Visit (up to 63 months)

  5. BMI Standard Deviation (SD) Score for Chronological Age Variation

    Mean changes of BMI SD score from Pretreatment and from Baseline are reported. SD score is a standard term used in growth studies and represents standard deviations calculated as the patient value minus the mean divided by the SD. SD scores vary depending on the age and sex of the child. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.

    Time frame: Months -6, 0, 12, 24, 36, 48 and Final Visit (up to 63 months)

  6. Auxological Parameters Variations: Height SD Score

    Mean changes of height SD score from Pretreatment and from Baseline are reported. SD score is a standard term used in growth studies and represents standard deviations calculated as the patient value minus the mean divided by the SD. SD scores vary depending on the age and sex of the child. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.

    Time frame: Months -6, 0, 12, 24, 36, 48 and Final Visit (up to 63 months)

  7. Auxological Parameters Variations: Growth Velocity SD Score

    Mean changes of growth velocity SD score from Pretreatment and from Baseline are reported. SD score is a standard term used in growth studies and represents standard deviations calculated as the patient value minus the mean divided by the SD. SD scores vary depending on the age and sex of the child. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.

    Time frame: Months -6, 0, 12, 24, 36, 48 and Final Visit (up to 63 months)

  8. Auxological Parameters Variations: Weight Variation

    Mean changes of weight from Pretreatment and from Baseline are reported. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.

    Time frame: Months -6, 0, 12, 24, 36, 48 and Final Visit (up to 63 months)

  9. Predicted Adult Height SD Score

    Mean change of predicted adult height SD score from Pretreatment and from Baseline are reported. SD score is a standard term used in growth studies and represents standard deviations calculated as the patient value minus the mean divided by the SD. SD scores vary depending on the age and sex of the child. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented. Also note that data for this endpoint was analysed for girls only.

    Time frame: Months -6, 0, 12 and Final Visit (up to 63 months)

  10. Bone Age Maturation

    Mean change in difference between bone age and chronological age from Pretreatment and from Baseline are reported. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.

    Time frame: Months -6, 0 and Final Visit (up to 63 months)

  11. Percentage of Girls With a Uterine Length < 36 Millimetres (mm)

    Percentage of girls who had a uterine length \< 36 mm are reported. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.

    Time frame: Months -6, 0, 12, 24, 36 and Final Visit (up to 63 months)

  12. Percentage of Children With a Stabilisation or Regression of Tanner Pubic Hair Pubertal Stage at the End of the Study (Final Visit), Compared to Pretreatment (Month -6) and Baseline (Month 0)

    Pubic hair was measured by the Tanner method on a scale of 1 to 6. A low grade (i.e. 1) corresponds to a pre-pubertal stage and a high grade (i.e. 5 or 6) to an adult stage. Percentage of patients who had stabilisation or regression (no change in grade or a reduced grade) of Tanner pubic hair pubertal stage is reported. Study treatment was to last until the end of the therapeutic period; visits for Months 36 and 48 were optional because if the girl was already 11 and the boy already 13, they would have finished the study at a prior visit. The Final Visit was to occur only if the child did not end the study by a complete visit such as at Months 24, 36 or 48. Please also note the additional post-hoc analysis for percentage of children with a stabilisation or regression of Tanner pubic hair pubertal stage which applied the variable Last Visit on Treatment instead of Final Visit.

    Time frame: Months 12, 24, 36, 48 and Final Visit (if applicable; up to 63 months)

07

Results

Posted May 1, 2017
Limitations and caveats
Since almost no hormonal data was collected after Baseline and only limited data was collected after Baseline for all other efficacy endpoints, only limited post-Baseline data is reported for the trial overall. All data analysed has been presented.

Participant flow

The study was designed as a multicentre study and included 10 investigational sites in France. This follow up study was to start on the day of the last visit (Month 6) of the phase III 2-54-52014-143 study and was to end when the Investigator judged that the patient had completed his/her treatment, i.e. at around 11 years in girls and 13 in boys.

Participant flow — Overall Study
MilestoneTriptorelin Pamoate 11.25 mg
Started35
Completed31
Not completed4
Withdrew: Adverse event1
Withdrew: Withdrawal by subject1
Withdrew: Lost to follow-up2

Outcome measures

PrimaryPercentage of Children With a Stabilisation or Regression of Tanner Pubertal Stage at the End of the Study (Final Visit), Compared to Pretreatment (Month -6) and Baseline (Month 0)

The primary objective was to assess efficacy of triptorelin pamoate 11.25 mg with respect to percentage of children maintaining a regression or stabilisation of sexual maturity (based on Tanner breast \[girls\] or genital \[boys\] pubertal stage) until end of study. Study treatment lasted until end of the therapeutic period; visits for Months 36 and 48 were optional since a child may have already finished the study at a prior visit. The Final Visit only occurred if the child did not end the study by a complete visit such as at Months 24, 36 or 48. Results are presented only for percentage of girls with regression or stabilisation of Tanner breast pubertal stage (n=34). Since only one boy was included in the study, results for this outcome measure were listed only and no statistical analysis was performed. Please also note additional post-hoc analysis for regression or stabilisation of Tanner breast pubertal stage which applied the variable Last Visit on Treatment instead of Final Visit.

Time frame:
Months 12, 24, 36, 48 and Final Visit (if applicable; up to 63 months)
Reported as:
Number · percentage of patients
Percentage of Children With a Stabilisation or Regression of Tanner Pubertal Stage at the End of the Study (Final Visit), Compared to Pretreatment (Month -6) and Baseline (Month 0)
percentage of patientsTriptorelin Pamoate 11.25 mg
Compared to Pretreatment (Month -6)61.8 (43.56 to 77.83)
Compared to Baseline (Month 0)52.9 (35.13 to 70.22)
SecondaryPercentage of Patients With a Suppressed Luteinizing Hormone (LH) Response to Gonadotropin-Releasing Hormone (GnRH) Test

A suppressed LH response to the GnRH test was defined as a stimulated peak of LH ≤3 international units per litre (IU/L). Percentage of patients who had a suppressed LH response to the GnRH test is reported. It should be noted that almost no hormonal data was collected after Baseline; all data analysed is presented.

Time frame:
Months -6, 0 and 36
Reported as:
Number · percentage of patients
Percentage of Patients With a Suppressed Luteinizing Hormone (LH) Response to Gonadotropin-Releasing Hormone (GnRH) Test
percentage of patientsTriptorelin Pamoate 11.25 mg
Pretreatment (Month -6)0 (NA to NA)
Baseline (Month 0)91.4 (76.94 to 98.20)
Month 36100 (2.50 to 100.00)
SecondaryLevels of Oestradiol in Girls or Testosterone in Boys Both Measured by Radioimmunoassay (RIA)

Mean levels of oestradiol in girls or testosterone in boys are reported. It should be noted that almost no hormonal data was collected after Baseline; all data analysed is presented.

Time frame:
Months -6, 0, 12, 36 and Final Visit (up to 63 months)
Reported as:
Mean · picograms per millilitre (pg/mL)
Levels of Oestradiol in Girls or Testosterone in Boys Both Measured by Radioimmunoassay (RIA)
picograms per millilitre (pg/mL)Triptorelin Pamoate 11.25 mg
Oestradiol at Pretreatment (Girls)18.59 ± 9.79
Oestradiol at Baseline (Girls)8.71 ± 4.51
Oestradiol at Month 12 (Girls)2.50 ± NA
Oestradiol at Month 36 (Girls)12.20 ± NA
Oestradiol at Final Visit (Girls)10.00 ± NA
Testosterone at Pretreatment (Boy)6.80 ± NA
Testosterone at Baseline (Boy)0.56 ± NA
SecondaryPercentage of Patients With a Suppressed Follicle Stimulating Hormone (FSH) Response to GnRH Test

A suppressed FSH response to the GnRH test was defined as a stimulated peak of FSH ≤3 IU/L. Percentage of patients who had a suppressed FSH response to the GnRH test is reported. It should be noted that almost no hormonal data was collected after Baseline; all data analysed is presented.

Time frame:
Months -6, 0 and 36
Reported as:
Number · percentage of patients
Percentage of Patients With a Suppressed Follicle Stimulating Hormone (FSH) Response to GnRH Test
percentage of patientsTriptorelin Pamoate 11.25 mg
Pretreatment (Month -6)0 (NA to NA)
Baseline (Month 0)82.9 (66.35 to 93.44)
Month 360 (NA to NA)
SecondaryBody Mass Index (BMI) for Chronological Age Variation

Mean changes of BMI from Pretreatment and from Baseline are reported. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.

Time frame:
Months -6, 0, 12, 24, 36, 48 and Final Visit (up to 63 months)
Reported as:
Mean · kilograms per metre squared (kg/m^2)
Body Mass Index (BMI) for Chronological Age Variation
kilograms per metre squared (kg/m^2)Triptorelin Pamoate 11.25 mg
Change from Pretreatment at Baseline0.43 ± 0.74
Change from Pretreatment at Month 121.60 ± 1.29
Change from Pretreatment at Month 241.69 ± 1.60
Change from Pretreatment at Month 361.69 ± 2.48
Change from Pretreatment at Month 481.06 ± 1.29
Change from Pretreatment at Final Visit2.39 ± 1.62
Change from Baseline at Month 121.14 ± 1.00
Change from Baseline at Month 241.43 ± 1.45
Change from Baseline at Month 361.53 ± 1.62
Change from Baseline at Month 481.34 ± 0.73
Change from Baseline at Final Visit1.91 ± 1.50
SecondaryBMI Standard Deviation (SD) Score for Chronological Age Variation

Mean changes of BMI SD score from Pretreatment and from Baseline are reported. SD score is a standard term used in growth studies and represents standard deviations calculated as the patient value minus the mean divided by the SD. SD scores vary depending on the age and sex of the child. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.

Time frame:
Months -6, 0, 12, 24, 36, 48 and Final Visit (up to 63 months)
Reported as:
Mean · SD score
BMI Standard Deviation (SD) Score for Chronological Age Variation
SD scoreTriptorelin Pamoate 11.25 mg
Change from Pretreatment at Baseline0.06 ± 0.27
Change from Pretreatment at Month 120.16 ± 0.37
Change from Pretreatment at Month 24-0.01 ± 0.37
Change from Pretreatment at Month 36-0.04 ± 0.63
Change from Pretreatment at Month 48-0.27 ± 0.68
Change from Pretreatment at Final Visit0.10 ± 0.46
Change from Baseline at Month 120.09 ± 0.27
Change from Baseline at Month 24-0.03 ± 0.27
Change from Baseline at Month 36-0.04 ± 0.38
Change from Baseline at Month 48-0.15 ± 0.45
Change from Baseline at Final Visit0.01 ± 0.36
SecondaryAuxological Parameters Variations: Height SD Score

Mean changes of height SD score from Pretreatment and from Baseline are reported. SD score is a standard term used in growth studies and represents standard deviations calculated as the patient value minus the mean divided by the SD. SD scores vary depending on the age and sex of the child. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.

Time frame:
Months -6, 0, 12, 24, 36, 48 and Final Visit (up to 63 months)
Reported as:
Mean · SD score
Auxological Parameters Variations: Height SD Score
SD scoreTriptorelin Pamoate 11.25 mg
Change from Pretreatment at Baseline0.09 ± 0.14
Change from Pretreatment at Month 12-0.05 ± 0.25
Change from Pretreatment at Month 24-0.24 ± 0.43
Change from Pretreatment at Month 36-0.83 ± 1.00
Change from Pretreatment at Month 48-1.68 ± 0.43
Change from Pretreatment at Final Visit-0.36 ± 0.53
Change from Baseline at Month 12-0.12 ± 0.22
Change from Baseline at Month 24-0.27 ± 0.43
Change from Baseline at Month 36-0.96 ± 0.74
Change from Baseline at Month 48-1.65 ± 0.38
Change from Baseline at Final Visit-0.43 ± 0.50
SecondaryAuxological Parameters Variations: Growth Velocity SD Score

Mean changes of growth velocity SD score from Pretreatment and from Baseline are reported. SD score is a standard term used in growth studies and represents standard deviations calculated as the patient value minus the mean divided by the SD. SD scores vary depending on the age and sex of the child. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.

Time frame:
Months -6, 0, 12, 24, 36, 48 and Final Visit (up to 63 months)
Reported as:
Mean · SD score
Auxological Parameters Variations: Growth Velocity SD Score
SD scoreTriptorelin Pamoate 11.25 mg
Change from Pretreatment at Baseline-1.85 ± 2.10
Change from Pretreatment at Month 12-2.44 ± 2.08
Change from Pretreatment at Month 24-3.18 ± 2.76
Change from Pretreatment at Month 36-6.97 ± 5.85
Change from Pretreatment at Month 48-6.96 ± 5.79
Change from Pretreatment at Final Visit-2.70 ± 2.47
Change from Baseline at Month 12-1.06 ± 1.44
Change from Baseline at Month 24-0.92 ± 1.50
Change from Baseline at Month 36-2.79 ± 1.18
Change from Baseline at Month 48-2.65 ± 1.01
Change from Baseline at Final Visit-1.09 ± 1.30
SecondaryAuxological Parameters Variations: Weight Variation

Mean changes of weight from Pretreatment and from Baseline are reported. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.

Time frame:
Months -6, 0, 12, 24, 36, 48 and Final Visit (up to 63 months)
Reported as:
Mean · kg
Auxological Parameters Variations: Weight Variation
kgTriptorelin Pamoate 11.25 mg
Change from Pretreatment at Baseline2.49 ± 1.53
Change from Pretreatment at Month 127.56 ± 3.47
Change from Pretreatment at Month 2410.13 ± 4.34
Change from Pretreatment at Month 3612.70 ± 7.05
Change from Pretreatment at Month 4812.20 ± 1.70
Change from Pretreatment at Final Visit13.17 ± 6.21
Change from Baseline at Month 125.06 ± 2.79
Change from Baseline at Month 248.21 ± 4.17
Change from Baseline at Month 3610.27 ± 5.11
Change from Baseline at Month 4810.85 ± 0.92
Change from Baseline at Final Visit10.65 ± 6.02
SecondaryPredicted Adult Height SD Score

Mean change of predicted adult height SD score from Pretreatment and from Baseline are reported. SD score is a standard term used in growth studies and represents standard deviations calculated as the patient value minus the mean divided by the SD. SD scores vary depending on the age and sex of the child. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented. Also note that data for this endpoint was analysed for girls only.

Time frame:
Months -6, 0, 12 and Final Visit (up to 63 months)
Reported as:
Mean · SD score
Predicted Adult Height SD Score
SD scoreTriptorelin Pamoate 11.25 mg
Change from Pretreatment at Baseline0.31 ± 0.18
Change from Pretreatment at Month 120.82 ± NA
Change from Pretreatment at Final Visit2.13 ± 0.87
Change from Baseline at Final Visit1.83 ± 0.64
SecondaryBone Age Maturation

Mean change in difference between bone age and chronological age from Pretreatment and from Baseline are reported. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.

Time frame:
Months -6, 0 and Final Visit (up to 63 months)
Reported as:
Mean · years
Bone Age Maturation
yearsTriptorelin Pamoate 11.25 mg
Change from Pretreatment at Baseline-0.16 ± 0.53
Change from Pretreatment at Final Visit-1.61 ± 1.04
Change from Baseline at Final Visit-1.69 ± 0.85
SecondaryPercentage of Girls With a Uterine Length < 36 Millimetres (mm)

Percentage of girls who had a uterine length \< 36 mm are reported. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.

Time frame:
Months -6, 0, 12, 24, 36 and Final Visit (up to 63 months)
Reported as:
Number · percentage of patients
Percentage of Girls With a Uterine Length < 36 Millimetres (mm)
percentage of patientsTriptorelin Pamoate 11.25 mg
Pretreatment42.4 (25.48 to 60.78)
Baseline41.2 (24.65 to 59.30)
Month 1216.7 (0.42 to 64.12)
Month 2450.0 (6.76 to 93.24)
Month 360 (NA to NA)
Final Visit25.0 (0.63 to 80.59)
SecondaryPercentage of Children With a Stabilisation or Regression of Tanner Pubic Hair Pubertal Stage at the End of the Study (Final Visit), Compared to Pretreatment (Month -6) and Baseline (Month 0)

Pubic hair was measured by the Tanner method on a scale of 1 to 6. A low grade (i.e. 1) corresponds to a pre-pubertal stage and a high grade (i.e. 5 or 6) to an adult stage. Percentage of patients who had stabilisation or regression (no change in grade or a reduced grade) of Tanner pubic hair pubertal stage is reported. Study treatment was to last until the end of the therapeutic period; visits for Months 36 and 48 were optional because if the girl was already 11 and the boy already 13, they would have finished the study at a prior visit. The Final Visit was to occur only if the child did not end the study by a complete visit such as at Months 24, 36 or 48. Please also note the additional post-hoc analysis for percentage of children with a stabilisation or regression of Tanner pubic hair pubertal stage which applied the variable Last Visit on Treatment instead of Final Visit.

Time frame:
Months 12, 24, 36, 48 and Final Visit (if applicable; up to 63 months)
Reported as:
Number · percentage of patients
Percentage of Children With a Stabilisation or Regression of Tanner Pubic Hair Pubertal Stage at the End of the Study (Final Visit), Compared to Pretreatment (Month -6) and Baseline (Month 0)
percentage of patientsTriptorelin Pamoate 11.25 mg
Compared to Pretreatment (Month -6)31.4 (16.85 to 49.29)
Compared to Baseline (Month 0)37.1 (21.47 to 55.08)
Post-hocPercentage of Girls With a Stabilisation or Regression of Tanner Breast Pubertal Stage at the End of the Study (Last Visit on Treatment), Compared to Pretreatment (Month -6) and Baseline (Month 0)

One primary efficacy endpoint was to assess efficacy of triptorelin pamoate 11.25 mg with respect to percentage of girls maintaining a regression or stabilisation of sexual maturity (based on Tanner breast pubertal stage) until end of study. Results reported for this primary endpoint applied the variable 'Final Visit' for comparison to Pretreatment and Baseline. Since it was determined that the majority of patients had a Final Visit \>3 months after their last injection, a post-hoc analysis of the percentage of girls with regression or stabilisation of Tanner breast pubertal stage was performed which applied the derived variable 'Last Visit on Treatment' to compare to the Pretreatment stage and to Baseline. This post-hoc analysis was judged to be appropriate since triptorelin pamoate 3-month formulation allows release of the active compound over 3 months and beyond this time, pubertal development is expected to progress.

Time frame:
Months 12, 24, 36, 48 and Last Visit on Treatment (if applicable; up to 51 months)
Reported as:
Number · percentage of patients
Percentage of Girls With a Stabilisation or Regression of Tanner Breast Pubertal Stage at the End of the Study (Last Visit on Treatment), Compared to Pretreatment (Month -6) and Baseline (Month 0)
percentage of patientsTriptorelin Pamoate 11.25 mg
Compared to Pretreatment (Month -6)91.2 (76.32 to 98.14)
Compared to Baseline (Month 0)91.2 (76.32 to 98.14)
Post-hocPercentage of Children With a Stabilisation or Regression of Tanner Pubic Hair Pubertal Stage at the End of the Study (Last Visit on Treatment), Compared to Pretreatment (Month -6)

One secondary efficacy endpoint in this study was the percentage of children who had stabilisation or regression (no change in grade or a reduced grade) of Tanner pubic hair pubertal stage at the end of the study. Results reported for this secondary endpoint applied the variable 'Final Visit' for comparison to Pretreatment and Baseline. Since it was determined that the majority of patients had a Final Visit \>3 months after their last injection, a post-hoc analysis of the percentage of children with regression or stabilisation of Tanner pubic hair pubertal stage was performed which applied the derived variable 'Last Visit on Treatment' for comparison to the Pretreatment stage. This post-hoc analysis was judged to be appropriate since triptorelin pamoate 3-month formulation allows release of the active compound over 3 months and beyond this time, pubertal development is expected to progress.

Time frame:
Months 12, 24, 36, 48 and Last Visit on Treatment (if applicable; up to 51 months)
Reported as:
Number · percentage of patients
Percentage of Children With a Stabilisation or Regression of Tanner Pubic Hair Pubertal Stage at the End of the Study (Last Visit on Treatment), Compared to Pretreatment (Month -6)
percentage of patientsTriptorelin Pamoate 11.25 mg
Percentage of Children With a Stabilisation or Regression of Tanner Pubic Hair Pubertal Stage at the End of the Study (Last Visit on Treatment), Compared to Pretreatment (Month -6)57.1

Adverse events

Collected over Up to 51 months (up to 48 months treatment + 3 months follow up). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Triptorelin Pamoate 11.25 mg—3/35 (8.6%)16/35 (45.7%)
Most frequent serious events
Most frequent serious events
EventTriptorelin Pamoate 11.25 mg
Gait disturbanceGeneral disorders1/35
Foot fractureInjury, poisoning and procedural complications1/35
MyalgiaMusculoskeletal and connective tissue disorders1/35
Vaginal haemorrhageReproductive system and breast disorders1/35
Most frequent other events
Most frequent other events
EventTriptorelin Pamoate 11.25 mg
Abdominal painGastrointestinal disorders6/35
Injection site painGeneral disorders4/35
HeadacheNervous system disorders3/35
Hot flushVascular disorders3/35
VomitingGastrointestinal disorders2/35
InsomniaPsychiatric disorders2/35
Pelvic painReproductive system and breast disorders2/35
Vaginal haemorrhageReproductive system and breast disorders2/35
CoughRespiratory, thoracic and mediastinal disorders2/35
Weight increasedInvestigations2/35

Baseline characteristics

Baseline characteristics are presented for Intention-To-Treat Population (ITT) population, consisting of all enrolled patients who received at least one injection of study treatment in this follow up study. These data were not re-collected at the start of the current study and are derived from data collected at Baseline of study 2-54-52014-143.

Age, Continuous
Age, Continuous(years)Triptorelin Pamoate 11.25 mg
Mean8.73 ± 1.07
Sex: Female, Male
Sex: Female, Male(Participants)Triptorelin Pamoate 11.25 mg
Female34
Male1
Weight at Pretreatment
Weight at Pretreatment(kilogram (kg))Triptorelin Pamoate 11.25 mg
Mean32.4 ± 6.9
08

Study locations

10 sites
  • Hôpital Hôtel Dieu (CHU)
    Angers, 49033, France
  • Medical Centre
    Bordeaux, 33000, France
  • Hôpital Flaubert
    Le Havre, 76083, France
  • Hôpital Archet II
    Nice, 06202, France
  • Hôpital Robert Debré
    Paris, 75019, France
  • American Memorial Hospital
    Reims, 51092, France
  • Hôpital Charles Nicolle
    Rouen, 76031, France
  • Hôpital Hautepierre
    Strasbourg, 67100, France
  • Hôpital de la Gespe
    Tarbes, 65013, France
  • Hôpital des Enfants
    Toulouse, 31026, France
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Apr 2015 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

Results were first posted in May 2017, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2009
First posted
May 29, 2009
Start
Apr 2008
Primary completionActual
Apr 2015
CompletionActual
Jan 2016
Results first posted
May 1, 2017
Last update
Jan 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00909844
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
May 29, 2009
Start date
Apr 2008
Primary completion
Apr 2015
Completion
Jan 2016
Results posted
May 1, 2017
Last update
Jan 15, 2019

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triptorelin

Start the discussion